Boehringer Ingelheim: CHMP recommends conditional marketing authorization for Spesolimab as first in class treatment option for generalized pustular psoriasis flares
CHMP positive opinion is based on evidence from the EFFISAYIL 1 trial, the largest clinical trial in patients with generalized pustular psoriasis (GPP) flares1 GPP is a rare and potentially